Skip to Content

Medical Device Toxicology: ISO 10993 Compliance, Chemical Characterization & Risk Assessment

13 July 2026 by
Medical Device Toxicology: ISO 10993 Compliance, Chemical Characterization & Risk Assessment
Auxochromofours Solutions Private Limited

While pharmaceutical products contain defined active ingredients with established toxicological profiles, medical devices comprise multiple engineering materials that may release trace chemicals during manufacturing, sterilization, storage, or clinical use. Conducting a scientifically robust toxicological risk assessment helps manufacturers evaluate these risks, achieve regulatory compliance, and confidently bring safe medical devices to market. 

These chemicals, commonly referred to as extractables and leachables, may migrate into surrounding tissues or enter systemic circulation. Evaluating their safety requires a multidisciplinary approach that combines analytical chemistry, toxicology, exposure science, and regulatory expertise.

Modern medical device risk assessment therefore involves:

  • Chemical characterization

  • Extractables and leachables testing

  • Exposure assessment

  • Biological evaluation

  • Toxicological risk assessment

  • Regulatory documentation

This science-based approach ensures patient safety while supporting successful regulatory submissions worldwide.

The Growing Importance of ISO 10993-17 and ISO 10993-18

The ISO 10993 standard series has transformed how manufacturers evaluate medical device safety. Rather than relying solely on animal studies, regulators now encourage manufacturers to perform detailed chemical analysis and toxicological risk assessments.

ISO 10993-18: Chemical Characterization

ISO 10993-18 focuses on identifying every chemical that could potentially migrate from a medical device.

Testing laboratories expose devices to aggressive extraction conditions using solvents such as:

  • Water

  • Ethanol

  • Hexane

  • Isopropyl alcohol

  • Simulated biological fluids

These extraction studies simulate worst-case clinical conditions to identify compounds that could enter the human body.

Advanced analytical techniques used include:

  • Gas Chromatography-Mass Spectrometry (GC-MS)

  • Liquid Chromatography-Mass Spectrometry (LC-MS)

  • ICP-MS for elemental impurities

  • FTIR spectroscopy

The resulting chemical profile becomes the foundation for toxicological evaluation.

ISO 10993-17: Toxicological Risk Assessment

Once chemicals are identified, toxicologists evaluate the safety of each compound.

The assessment includes:

  • Reviewing published toxicological literature

  • Identifying NOAEL (No Observed Adverse Effect Level)

  • Determining LOAEL (Lowest Observed Adverse Effect Level)

  • Calculating Tolerable Intake (TI)

  • Applying Toxicological Thresholds (TT)

  • Estimating Margin of Safety (MoS)

If sufficient toxicological information is unavailable, partnering with experienced toxicology experts like Auxochromofours can help manufacturers apply scientifically validated read-across methodologies, threshold-based approaches, and regulatory best practices to accurately assess patient exposure and support global compliance.

Each identified compound is assessed for:

  • Systemic toxicity

  • Carcinogenicity

  • Genotoxicity

  • Reproductive toxicity

  • Endocrine disruption

  • Organ-specific toxicity

Understanding Extractables and Leachables (E&L)

Extractables are chemical compounds that can be released from a material under aggressive laboratory extraction conditions, whereas leachables are substances that migrate from a medical device during its intended clinical use. Understanding the difference between extractables and leachables is essential for accurate toxicological risk assessment, regulatory compliance, and patient safety. For a deeper understanding of extractables and leachables (E&L) risk assessment and their role in regulatory submissions, explore Auxochromofours' comprehensive guide on the topic. 

Both are critical components of ISO 10993 compliance because even trace quantities of harmful substances can affect patient safety, particularly in long-term implantable devices.

A comprehensive extractables and leachables study helps manufacturers:

  • Identify unknown chemicals

  • Quantify patient exposure

  • Support regulatory submissions

  • Reduce approval delays

  • Improve product safety

Material-Specific Toxicological Challenges

Medical devices consist of a wide variety of engineering materials, each presenting unique toxicological concerns.

Polymers and Plastics

Medical-grade polymers such as polyurethane, silicone, polyethylene, polypropylene, and PVC may contain:

  • Residual monomers

  • Plasticizers

  • Antioxidants

  • Stabilizers

  • Processing aids

These substances can gradually migrate from the polymer matrix over time, making detailed chemical characterization essential.

Metals and Metallic Alloys

Many implantable devices use materials including:

  • Titanium

  • Stainless steel

  • Nitinol

  • Cobalt-chromium alloys

Mechanical wear and corrosion may release metal ions such as nickel, cobalt, and chromium, potentially causing:

  • Local inflammation

  • Allergic reactions

  • Tissue toxicity

  • Systemic immune responses

Coatings, Adhesives, and Colorants

Medical devices often include:

  • Surface coatings

  • Lubricants

  • Printing inks

  • Adhesives

  • Biodegradable polymers

Over time, these materials may degrade and produce additional chemical compounds that require toxicological evaluation before regulatory approval.

Worst-Case Exposure Assessment

Unlike medicines with fixed doses, medical devices have no simple dosage calculation. Toxicologists therefore use conservative exposure models to estimate patient risk.

Long-Term Implant Exposure

Permanent implants such as pacemakers, orthopedic implants, and vascular stents may remain inside the body for decades.

Risk assessments assume:

  • Maximum possible chemical release

  • Continuous patient exposure

  • Long-term accumulation within tissues

These conservative assumptions provide a strong safety margin.

Surface Area Considerations

Device geometry significantly affects chemical release.

Products with:

  • Large surface areas

  • Porous structures

  • Extended tissue contact

  • High fluid exposure

can generate greater extractable concentrations than simple devices.

Consequently, toxicologists consider:

  • Surface area

  • Contact duration

  • Route of exposure

  • Clinical indication

  • Intended patient population

Global Regulatory Expectations

Although ISO 10993 provides an internationally accepted framework, regulatory authorities often apply additional requirements.

US FDA

The FDA places considerable emphasis on:

  • Comprehensive chemical characterization

  • Low Analytical Evaluation Thresholds (AET)

  • Scientific justification for unknown compounds

  • Device-specific biological evaluation

Manufacturers must provide robust evidence supporting the safety of every detected chemical.

European Union MDR (2017/745)

The EU Medical Device Regulation introduces additional scrutiny for substances classified as:

  • Carcinogenic

  • Mutagenic

  • Reprotoxic (CMR)

  • Endocrine disruptors

Manufacturers must justify the presence of hazardous substances above regulatory thresholds and demonstrate that safer alternatives have been considered.

Best Practices for Medical Device Toxicological Risk Assessment

To streamline regulatory approval and ensure patient safety, manufacturers should:

  • Perform chemical characterization early in product development.

  • Conduct comprehensive extractables and leachables studies.

  • Maintain complete material composition records.

  • Generate scientifically robust toxicological risk assessments.

  • Follow the latest ISO 10993 guidance documents.

  • Monitor evolving FDA and EU MDR regulatory expectations.

  • Collaborate with experienced regulatory toxicologists throughout product development.

A proactive approach minimizes regulatory delays, reduces product development risks, and improves global market acceptance.

Conclusion

Medical device toxicology has evolved into a highly specialized field that combines analytical chemistry, toxicology, material science, and regulatory compliance. Rather than relying solely on traditional biocompatibility testing, manufacturers must now identify, quantify, and assess every chemical that may migrate from a device throughout its lifecycle.

Comprehensive ISO 10993 toxicological risk assessments, chemical characterization, and extractables and leachables studies are essential for meeting FDA, EU MDR, and international regulatory requirements. By adopting a science-based, risk-driven approach, manufacturers can accelerate product approvals, ensure long-term patient safety, and maintain compliance in an increasingly demanding regulatory landscape.

Frequently Asked Questions (FAQs)


1. What is medical device toxicology?

Medical device toxicology evaluates the potential health risks associated with chemicals released from medical devices during their intended use, ensuring they are safe for patients.

2. What is ISO 10993?

ISO 10993 is an internationally recognized standard series that outlines the biological evaluation and biocompatibility requirements for medical devices.

3. What is the difference between ISO 10993-17 and ISO 10993-18?

ISO 10993-18 focuses on chemical characterization and identifying extractable compounds, while ISO 10993-17 evaluates the toxicological risks associated with those identified chemicals.

4. What are extractables and leachables?

Extractables are chemicals released under aggressive laboratory conditions, whereas leachables are substances that migrate from a medical device during normal clinical use.

5. Why is toxicological risk assessment important for medical devices?

It helps determine whether patient exposure to chemicals released from a device remains within scientifically accepted safety limits and supports global regulatory approval.

6. Which analytical techniques are commonly used for chemical characterization?

Common techniques include GC-MS, LC-MS, ICP-MS, FTIR spectroscopy, and other advanced analytical methods for identifying and quantifying chemical compounds.

7. Which regulatory agencies require ISO 10993 compliance?

Major regulatory authorities, including the US FDA, European Union MDR, Health Canada, PMDA (Japan), and many other global agencies, reference ISO 10993 during medical device evaluations.

8. How can expert toxicology consulting support medical device manufacturers?

Experienced toxicology consultants can perform chemical characterization reviews, toxicological risk assessments, regulatory gap analyses, and ISO 10993 compliance evaluations to help manufacturers achieve faster regulatory approvals while ensuring patient safety.